Cytokinetics, Incorporated — Q2 2023 Form 10-Q
Business context and reporting period. The company is a late-stage biopharmaceutical developer of muscle-directed medicines, with its most advanced programs focused on aficamten for hypertrophic cardiomyopathy (HCM) and omecamtiv mecarbil for heart failure. This unaudited report covers the three and six months ended June 30, 2023; comparisons are with the same 2022 periods. Cytokinetics has not generated revenue from commercial product sales.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $0.9 million | $89.0 million | $5.5 million | $90.1 million |
| Operating expenses | $122.9 million | $99.8 million | $252.0 million | $178.8 million |
| Operating loss | $122.0 million | $10.9 million | $246.5 million | $88.7 million |
| Net loss | $128.6 million | $19.8 million | $259.9 million | $109.3 million |
| Net loss per share, basic and diluted | $1.34 | $0.23 | $2.72 | $1.28 |
| Research and development expense | $83.2 million | $57.1 million | $162.6 million | $103.1 million |
| General and administrative expense | $39.7 million | $42.7 million | $89.4 million | $75.8 million |
- Revenue and comparability: Q2 2022 included $87.0 million of nonrecurring revenue from extinguishment of a mavacamten royalty obligation. The first half of 2023 included a $2.5 million aficamten milestone recognized for anticipated initiation of an nHCM Phase 3 trial; the related contractual payment right had not yet arisen at June 30. Q2 2023 revenue was primarily Astellas reimbursement.
- Cash flow: For the first half of 2023, operating activities used $244.1 million, versus $117.3 million in 2022; investing activities provided $247.6 million, versus $1.0 million; financing activities used $1.7 million, versus providing $97.3 million. The 2022 financing comparison included Royalty Pharma proceeds.
- Liquidity: Cash, cash equivalents and investments totaled $592.6 million at June 30, 2023, down from $829.3 million at December 31, 2022. Working capital was $521.0 million. Management believes existing cash, investments and investment income will fund projected requirements for at least 12 months after the report’s issuance.
- Debt and other obligations: Borrowings, net of issuance costs, totaled $609.8 million: $62.5 million term loan, $20.7 million 2026 convertible notes and $526.6 million 2027 convertible notes. Separately, liabilities for royalty participation agreements were $313.2 million. The company reported a $333.1 million stockholders’ deficit. Undiscounted Oyster Point lease payments totaled $214.5 million.
- Margins: The filing reports operating and net losses, but does not provide a meaningful product gross margin; the company has no commercial product sales.
Material changes and business developments
- R&D expense rose $26.1 million in Q2 and $59.6 million in the first half, primarily due to clinical work on COURAGE-ALS, cardiac muscle inhibitor programs and early research. COURAGE-ALS and its extension accounted for $15.3 million of Q2 and $30.7 million of first-half 2023 R&D expense; the company expected related costs to decline in the second half.
- G&A expense fell $3.0 million in Q2 year over year, mainly on lower outside-service costs, but rose $13.6 million for the first half, reflecting outside services and personnel-related costs, including stock compensation.
- The company received an FDA Complete Response Letter for omecamtiv mecarbil on February 28, 2023. FDA said GALACTIC-HF was not sufficiently persuasive and an additional clinical trial was required. Cytokinetics said it had no plans to conduct another trial; U.S. approval therefore remains uncertain. European and Chinese applications were under review.
- On March 31, 2023, Cytokinetics discontinued the Phase 3 COURAGE-ALS trial and its open-label extension after the trial was determined futile.
- Aficamten remained the principal development focus. SEQUOIA-HCM enrollment was complete at 282 patients, with topline results expected by year-end 2023. The company expected to start ACACIA-HCM, a Phase 3 nHCM trial, in September 2023; it reported positive Phase 2 Cohort 4 results. MAPLE-HCM enrollment began August 3, 2023, after the quarter.
Outlook, risks and unusual items
- Management expects continuing operating losses and cash outflows. It cited potential strategic collaborations, equity issuance, grants and debt financing as possible funding sources, while warning that additional capital may not be available on acceptable terms or at all.
- The filing refers to 2023 revenue and net-cash-use guidance but the provided filing text does not give a clear numerical guidance value.
- Omecamtiv mecarbil faces material regulatory uncertainty after the FDA letter; a further clinical trial could entail significant cost and delay. Related Royalty Pharma financing tranches of $75 million and $50 million tied to aficamten development remain conditional; the $50 million and $25 million omecamtiv-related tranches are unavailable because their conditions were not met.
- Royalty-liability carrying values and non-cash interest expense depend on management estimates of future product sales, launch timing and market conditions. Changes in those assumptions affected reported interest expense during the period.
- Principal risks include clinical and regulatory failure or delay, dependence on contract manufacturers and CROs, reliance on Ji Xing for development in China and Taiwan, potential need for additional financing, competition, reimbursement and pricing uncertainty, intellectual-property risk, and debt and royalty obligations.
- The company reported no legal proceedings and no subsequent events in the financial-statement note. Management concluded disclosure controls were effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported.
Most important facts for investors to verify
- Whether aficamten’s SEQUOIA-HCM results met the primary endpoint and support regulatory filings, and whether the anticipated ACACIA-HCM and MAPLE-HCM timelines were achieved.
- Any further FDA or other regulatory updates on omecamtiv mecarbil, and the status of European and Chinese reviews.
- Actual cash burn, cash and investment balances, and whether management’s stated 12-month liquidity expectation remains supported by subsequent results.
- Availability and conditions for the remaining Royalty Pharma loan or revenue-interest proceeds, and the effect of royalty obligations on future economics.
- Progress and costs associated with commercial readiness, clinical programs and financing, including any use of the $300 million ATM facility.